麻豆传媒

Dr. Edelmayer leads efforts to accelerate the scientific agenda of the Alzheimer鈥檚 Association through the creation and delivery of ongoing research education. She engages with more than 75 Alzheimer鈥檚 Association chapters across the country, ensuring that staff and the public are aware of the importance of medical research and the Association鈥檚 crucial role in advancing research to improve the lives of individuals living with dementia and their care partners. In addition, Dr. Edelmayer manages initiatives uniting researchers and clinicians with leaders of industry, regulatory agencies and the government on topics related to blood-based biomarker testing, use of digital health technologies and biotech approaches in studying dementia.

Dr. Edelmayer has over 17 years of experience as a practicing scientist and educator. She spent more than six years as a pharmacologist in the Neuroscience and Immunology Discovery Divisions at Abbott and AbbVie, where she was recognized as an emerging scientific leader. As a senior scientist, she led a digital pathology team, conducted research and supported the development of clinical therapeutics in chronic inflammatory diseases of the nervous system and the skin. Dr. Edelmayer has lectured, published and led collaborations in areas of neurophysiology, inflammatory skin pathology and pain neurobiology.

She completed her Ph.D. and postdoctoral training in medical pharmacology with a focus on neuropharmacology at the University of Arizona College of Medicine. Dr. Edelmayer holds a bachelor鈥檚 degree in neuroscience from the University of Pittsburgh, where she also completed a National Institute of Mental Health Research Fellowship. 

Dr. Piomelli was trained in neuroscience and pharmacology. Research in his lab is focused on the function of lipid-derived messengers, with particular emphasis on the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Current research efforts converge on three areas: formation and deactivation of anandamide and 2-arachidonylglycerol; physiological roles of the endogenous cannabinoid system; development of therapeutic agents that target anandamide and 2-arachidonylglycerol metabolism. Primary neural cell cultures and state-of-the-art analytical techniques such as liquid chromatography/mass-spectrometry are used to investigate formation and deactivation of anandamide and 2-arachidonoylglycerol in brain cells. Protein purification and cloning approaches are employed to characterize the molecular mechanisms underlying these processes. Cellular pharmacology and medicinal chemistry, in collaboration with leading international labs, are used to identify pharmacological agents that interfere with various aspects of endogenous cannabinoid function, and their therapeutic potential is explored in vitro and in vivo.